To include your compound in the COVID-19 Resource Center, submit it here.

Indivior's Sublocade MAT to compete with Alkermes’ Vivitrol

FDA approved once-monthly subcutaneous Sublocade buprenorphine (RBP-6000) from Indivior plc (LSE:INDV) to treat opioid use disorder. The company said it expects to launch the drug next quarter at a wholesale

Read the full 307 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE